The International journal of pharmacy practice · 2026
Hepatitis C virus drug-drug interactions: a comparison of online drug interaction databases.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Drwiega Emily N, Martin Michelle T, Badowski Melissa E
Аннотация
OBJECTIVES: The purpose of this study was to quantify and compare potential drug-drug interactions between hepatitis C medications and comedications across six online drug-drug interaction databases.
METHODS: Investigators assessed drug-drug interactions between prescription and non-prescription medications with ribavirin and five hepatitis C virus direct-acting antiviral regimens, across online drug-drug interaction databases. The primary outcome was the number of drug pairs that resulted in potential interactions.
KEY FINDINGS: A total of 1488 medication pairs were evaluated for each database and varying potential interactions were identified. Variability also existed among identification of potentially contraindicated drug pairs, and only 2 of 41 (4.9%) of these pairs were identified as contraindicated by all 6 databases.
CONCLUSIONS: Due to institutional differences and inconsistencies in the identification of potential drug-drug interactions, clinical judgment is imperative, and cross-referencing multiple databases can offer additional insight.
METHODS: Investigators assessed drug-drug interactions between prescription and non-prescription medications with ribavirin and five hepatitis C virus direct-acting antiviral regimens, across online drug-drug interaction databases. The primary outcome was the number of drug pairs that resulted in potential interactions.
KEY FINDINGS: A total of 1488 medication pairs were evaluated for each database and varying potential interactions were identified. Variability also existed among identification of potentially contraindicated drug pairs, and only 2 of 41 (4.9%) of these pairs were identified as contraindicated by all 6 databases.
CONCLUSIONS: Due to institutional differences and inconsistencies in the identification of potential drug-drug interactions, clinical judgment is imperative, and cross-referencing multiple databases can offer additional insight.